Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 17/20 | 0.56 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PTGIR | P43119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3391044 | 0.91 | PTGDR2 (0.66) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL136154 | 0.87 | PTGDR2 (0.64) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL3390392 | 0.84 | PTGDR2 (0.44) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL3386649 | 0.84 | PTGDR2 (0.59) | PTGDR2PTGDRCYP3A4TBXA2RKDM4E | |
| SCHEMBL136366 | 0.84 | PTGDR2 (0.58) | PTGDR2PTGDRCYP3A4TBXA2RKDM4E | |
| SCHEMBL3390791 | 0.84 | APP (0.48) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL137248 | 0.83 | PTGDR2 (0.59) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL136264 | 0.82 | PTGDR2 (0.65) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 | |
| SCHEMBL9982543 | 0.82 | PTGDR2 (0.56) | PTGDR2PTGDRCYP3A4TBXA2RALDH1A1 | |
| SCHEMBL134955 | 0.81 | PTGDR2 (0.62) | PTGDR2PTGDRCYP3A4TBXA2RCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378107-B2 | Heteroaryl antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-29 | — | — | US | disclosed |
| WO-2010039977-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010039977-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319445-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885CYP3A4 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.